News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Rapport Therapeutics CEO Abraham Ceesay sold 22,541 shares of the company's stock for approximately $1.04 million, reducing his direct ownership by 4.19%. This sale follows other recent transactions by Ceesay. Despite a recent stock decline and a missed earnings estimate, analysts maintain a "Moderate …
Rapport Therapeutics (RAPP) CEO Abraham Ceesay sold 51,499 shares of common stock on August 10–11, 2026, through Rule 10b5-1 trading plans adopted on March 27, 2026. The sales occurred at weighted average prices between approximately $45.97 and $48.62 per share. Following these transactions, Ceesay's …
Rapport Therapeutics (NASDAQ:RAPP) recently hit a new 52-week high of $48.94, with its shares trading near $48.82. Despite a quarterly loss of $1.19 per share, missing consensus estimates, analyst sentiment remains "Moderate Buy" with an average price target of $57.86. Institutional investors have increased …
Rapport Therapeutics (RAPP) reported widening net losses for Q2 2026 and the first half of the year, with net losses more than doubling year-over-year in Q2. This indicates the company remains an early-stage, cash-consuming entity focused on its neurology pipeline, particularly the RAP-219 program. …
Wall Street Zen downgraded Rapport Therapeutics (NASDAQ:RAPP) to a "sell" rating, contrasting with a broader analyst consensus of "Moderate Buy" and an average target price of $57.86. The company recently reported a quarterly loss of $1.19 per share, missing analyst estimates, and insiders have …
This article provides stock information for Rapport Therapeutics Inc (RAPP) on TradingKey, noting its current stock price of $45.490 with a slight decrease of 1.86%. It highlights that more news for the company is expected soon and directs users to various sections like financial …
Rapport Therapeutics, Inc. (NASDAQ:RAPP) has received a "Moderate Buy" consensus rating from twelve brokerages, with an average 12-month price target of $57.86, exceeding its current share price of $46.35. The company's stock has seen a sharp increase, trading near its 12-month high, despite a …
Rapport Therapeutics (RAPP) has gained investor attention following positive second-quarter 2026 results and progress in its central nervous system pipeline, including new Phase 3 trials for RAP-219. The company's share price has seen significant increases, but it remains a loss-making entity. While its Price-to-Book …
Analysts have provided new ratings for Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA). Goldman Sachs maintained a Buy rating for Rapport Therapeutics with a $62.00 price target, while UBS maintained a Hold rating for Honeywell Aerospace with a $213.00 price target. The consensus …
Rapport Therapeutics Inc. stock reached an all-time high of $44.38, marking a 190% increase over the past year and a 57% six-month return. Despite its current market capitalization of $2.03 billion suggesting it's overvalued, the surge reflects strong investor confidence. Analysts maintain a positive …
Rapport Therapeutics, Inc. reported no revenue in Q2 2026 and a net loss of $(56.6)M, or $(1.19) diluted EPS, an increase from Q2 2025 as the company scales its clinical programs. The company advanced its RAP-219 clinical program into Phase 3, recognized a $20.0M …
This document is the Q2 2026 Earnings Report in the form of a 10-Q filing for Rapport Therapeutics. It contains the company's financial results and relevant disclosures for the second quarter of 2026.
* Rapport Therapeutics press release [https://seekingalpha.com/pr/20607480-rapport-therapeutics-reports-second-quarter-2026-financials-and-provides-business-update] (RAPP [https://seekingalpha.com/symbol/RAPP]): Q2 net Loss was $56.6M, as compared to $26.7M for the prior year period. * RAPP expects that cash, cash equivalents, and short-term investments as of June 30, 2026, will enable it to fund its operating …
This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting weak near-term sentiment but strong long-term prospects. It identifies an exceptional 50.4:1 risk-reward setup and provides AI-generated trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal …
Rapport Therapeutics reported a Q2 2026 net loss of $56.6 million, primarily due to increased R&D and SG&A expenses. Despite the loss, the company has advanced its lead candidate, RAP-219, initiating Phase 3 trials for focal onset seizures (FOCUS 1 and FOCUS 2) and …
William Blair initiated coverage on Rapport Therapeutics Inc. (NASDAQ:RAPP) with an outperform rating and a fair value of $79.03 per share. The biotechnology company, which focuses on neurology and neuropsychiatry disorders, has seen significant analyst attention recently. The stock is currently trading at $42.15, …
This article analyzes the market sentiment for Rapport Therapeutics (RAPP) based on analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target of $48, a short interest of 7.5%, and insider activity …
This article provides institutional shareholding data for Rapport Therapeutics Inc (RAPP), listing the top institutional investors and their respective shareholdings and percentage changes. Key investors include Third Rock Ventures, Fidelity Management, and ARCH Venture Partners, with several showing significant increases in their holdings. The …
Rapport Therapeutics Inc (RAPP) saw its stock price rise by 3.61% to $42.150. The company, a clinical-stage biotechnology firm, focuses on developing precision medicines for neurological and psychiatric disorders, utilizing its RAP technology platform. Analyst ratings for RAPP are predominantly "Buy," with a target …
This article provides a technical analysis of Rapport Therapeutics Inc (RAPP), detailing its current support, resistance levels, and the readings from various technical indicators and moving averages. It offers a summary of "Sell," "Neutral," and "Buy" signals based on indicators like MACD, RSI, and …
The article details the shareholder structure of Rapport Therapeutics Inc (RAPP), listing major shareholders like Third Rock Ventures, Fidelity Management, and ARCH Venture Partners, along with their respective proportions. It also categorizes shareholders by type (e.g., Investment Advisor, Venture Capital) and provides a history …
This article provides financial information for Rapport Therapeutics, Inc. (NASDAQ: RAPP), specifically focusing on its forward price-to-earnings ratio. It is presented within the TradingView platform interface, indicating it's a data point rather than a detailed analytical piece. The content confirms the company's listing on …
Rapport Therapeutics Inc. (NASDAQ: RAPP) is showing a near-term strong sentiment, moving towards long-term positive bias with a mid-channel oscillation pattern. The analysis highlights an exceptional risk-reward setup, targeting a 15.7% gain against a 0.3% risk. Three distinct AI-generated trading strategies are provided for …
Search by ticker symbol or company name and select a result to open its chart.